Regulatory T cell frequency, but not plasma IL-33 levels, represents potential immunological biomarker to predict clinical response to intravenous immunoglobulin therapy
Authors:
- Mohan S. MaddurMMMohan S. Maddur
- Emmanuel Stephen-VictorESEmmanuel Stephen-Victor
- Mrinmoy DasMDMrinmoy Das
- Praveen PrakharPPPraveen Prakhar
- Varun K. SharmaVSVarun K. Sharma
- Vikas SinghVSVikas Singh
- Magalie RabinMRMagalie Rabin
- Jamma TrinathJTJamma Trinath
- Kithiganahalli N. BalajiKBKithiganahalli N. Balaji
- Francis BolgertFBFrancis Bolgert
- Jean-Michel VallatJVJean-Michel Vallat
- Laurent MagyLMLaurent Magy
Open Access
- 20 March 2017
- journal article
- research article
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 14 (1) , 1-8
Abstract
Intravenous immunoglobulin (IVIG) is a polyspecific pooled immunoglobulin G preparation and one of the commonly used therapeutics for autoimmune diseases including those of neurological origin. A recent report in murine model proposed that IVIG expands regulatory T (Treg) cells via induction of interleukin 33 (IL-33). However, translational insight on these observations is lacking. Ten newly diagnosed Guillain-Barré syndrome (GBS) patients were treated with IVIG at the rate of 0.4 g/kg for three to five consecutive days. Clinical evaluation for muscular weakness was performed by Medical Research Council (MRC) and modified Rankin scoring (MRS) system. Heparinized blood samples were collected before and 1, 2, and 4–5 weeks post-IVIG therapy. Peripheral blood mononuclear cells were stained for surface CD4 and intracellular Foxp3, IFN-γ, and tumor necrosis factor alpha (TNF-α) and were analyzed by flow cytometry. IL-33 and prostaglandin E2 in the plasma were measured by ELISA. The fold changes in plasma IL-33 at week 1 showed no correlation with the MRC and MRS scores at weeks 1, 2, and ≥4 post-IVIG therapy. Clinical recovery following IVIG therapy appears to be associated with Treg cell response. Contrary to murine study, there was no association between the fold changes in IL-33 at week 1 and Treg cell frequency at weeks 1, 2, and ≥4 post-IVIG therapy. Treg cell-mediated clinical response to IVIG therapy in GBS patients was associated with reciprocal regulation of effector T cells-expressing TNF-α. Treg cell expansion by IVIG in patients with autoimmune diseases lack correlation with IL-33. Treg cell frequency, but not plasma IL-33 levels, represents potential immunological biomarker to predict clinical response to IVIG therapy.Keywords
This publication has 41 references indexed in Scilit:
- Recombinant IL-33 prolongs leflunomide-mediated graft survival by reducing IFN-γ and expanding CD4+Foxp3+ T cells in concordant heart transplantationLaboratory Investigation, 2016
- Sialylated intravenous immunoglobulin suppress anti-ganglioside antibody mediated nerve injuryExperimental Neurology, 2016
- IVIg for relapsing–remitting multiple sclerosis: promises and uncertaintiesTrends in Pharmacological Sciences, 2015
- Molecular and immunological biomarkers to predict IVIg responseTrends in Molecular Medicine, 2015
- Intravenous immunoglobulin therapy: how does IgG modulate the immune system?Nature Reviews Immunology, 2013
- Tregitope update: Mechanism of action parallels IVIgAutoimmunity Reviews, 2013
- Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulinJournal of Allergy and Clinical Immunology, 2011
- Clinical features, pathogenesis, and treatment of Guillain-Barré syndromeThe Lancet Neurology, 2008
- Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitisBlood, 2008
- Intravenous Immunoglobulin Therapy Affects T Regulatory Cells by Increasing Their Suppressive FunctionThe Journal of Immunology, 2007